(1S)-N-methyl-1-[(2S)-oxiran-2-yl]-2-phenylethanamine | 238753-80-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (1S)-N-methyl-1-[(2S)-oxiran-2-yl]-2-phenylethanamine
• CAS: 238753-80-5
• 化学式: C₁₁H₁₅NO
• 分子量: 177.246
• InChiKey: ILQDWSUQUPYARS-WDEREUQCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  24.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (1S)-N-methyl-1-[(2S)-oxiran-2-yl]-2-phenylethanamine 在 sodium hydroxide 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 8.0h， 生成 [(1S,2R)-1-Benzyl-2-(tert-butyl-dimethyl-silanyloxy)-pent-4-enyl]-methyl-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Total Synthesis of the Multidrug-Resistance Reversing Agent Hapalosin

  摘要：

  DOI：

  10.1055/s-1999-2765
• 作为产物：
  描述：

  (R)-1-(oxiran-2-yl)-2-phenylethanone 、 甲胺 在 4 A molecular sieve 、 溶剂黄146 、 tetramethylammonium triacetoxyborohydride 作用下， 以 二氯甲烷 为溶剂， 反应 15.0h， 以70%的产率得到(1S)-N-methyl-1-[(2S)-oxiran-2-yl]-2-phenylethanamine
  参考文献：
  名称：

  Total Synthesis of the Multidrug-Resistance Reversing Agent Hapalosin

  摘要：

  DOI：

  10.1055/s-1999-2765

文献信息

• METHODS FOR THE PREPARATION OF N-ISOBUTYL-N-(2-HYDROXY-3-AMINO-4-PHENYLBUTYL)-P-NITROBENZENESULFONYLAMIDE DERIVATIVES
  申请人：Zinser Hartmut Burghard

  公开号：US20100121094A1

  公开（公告）日：2010-05-13

  A process for the preparation of N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl)-p-nitrobenzenesulfonylamide derivatives in which a (1-benzyl-2-hydroxy-3-isobutyl-amino-propyl)-carbamic acid derivative is reacted with a p-nitrophenylsulfonyl halide to provide the desired product in a high yield and degree of purity.

  一种制备N-异丁基-N-(2-羟基-3-氨基-4-苯基丁基)-对硝基苯磺酰胺衍生物的方法，其中将(1-苄基-2-羟基-3-异丁基氨基丙基)-氨基甲酸衍生物与对硝基苯磺酰卤素反应，以高收率和纯度提供所需的产物。
• PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B] FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL] (ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE
  申请人：Wigerinck Piet Tom Bert Paul

  公开号：US20110160468A1

  公开（公告）日：2011-06-30

  The present invention relates to a process for the preparation of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate as well as novel intermediates for use in said process. (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate is particularly useful as an HIV protease inhibitor.

  本发明涉及一种制备（3R,3aS,6aR）-六氢呋喃[2,3-b]呋喃-3-基（1S,2R）-3-[[(4-氨基苯基)磺酰](异丁基)氨基]-1-苄基-2-羟基丙基氨基甲酸酯的方法，以及用于该方法的新型中间体。 （3R,3aS,6aR）-六氢呋喃[2,3-b]呋喃-3-基（1S,2R）-3-[[(4-氨基苯基)磺酰](异丁基)氨基]-1-苄基-2-羟基丙基氨基甲酸酯特别适用于作为HIV蛋白酶抑制剂。
• N-ETHYL HYDROXYETHYLAMINE USEFUL IN TREATING CNS CONDITIONS
  申请人：Kleinman F. Edward

  公开号：US20070213368A1

  公开（公告）日：2007-09-13

  An N-ethyl hydroxyethyleneamine of formula (I) are disclosed which are useful in treating CNS conditions, including neurodegenerative diseases such as Alzheimer's Disease.
• N-methyl hydroxyethylamine useful in treating CNS conditions
  申请人：Kleinman Edward F.

  公开号：US20080132552A1

  公开（公告）日：2008-06-05

  An N-methyl hydroxyethyleneamine useful in treating CNS conditions, including neurodegenerative ones such as Alzheimer's Disease, is disclosed.
• SMALL MOLECULE ENTRY INHIBITORS
  申请人：Surleraux Dominique Louis

  公开号：US20090203743A1

  公开（公告）日：2009-08-13

  The present invention concerns the compounds having the formula N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites thereof, wherein R 1 and R 8 each are H, optionally substituted C 1-6 alkyl, C 2-6 alkenyl, C 3-7 cycloalkyl, aryl, Het 1 , Het 2 ; R 1 may also be a radical of formula (R 11a R 11b )NC(R 10a R 10b )CR 9 —; t is 0, 1 or 2; R 2 is H or C 1-6 alkyl; L is —C(═O)—, —O—C(═O)—, —NR 8 —C(═O)—, —O—C 1-6 alkanediyl-C(═O)—, —NR 8 —C 1-6 alkanediyl-C(═O)—, —S(═O) 2 —, —O—S(═O) 2 —, —NR 8 —S(═O) 2 ; R 3 is C 1-6 alkyl, aryl, C 3-7 cycloalkyl, C 3-7 cycloalkylC 1-4 alkyl, or arylC 1-4 alkyl; R 4 is H, C 1-4 alkylOC(═O), carboxyl, aminoC(═O), mono- or di(C 1-4 alkyl)aminoC(═O), C 3-7 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl or optionally substituted C 1-6 alkyl; A is C 1-6 alkanediyl, —C(═O)—, —C(═S)—, —S(═O) 2 —, C 1-6 alkanediyl-C(═O)—, C 1-6 alkanediyl-C(═S)— or C 1-6 alkanediyl-S(═O) 2 —; R 5 is H, OH, C 1-6 alkyl, Het 1 C 1-6 alkyl, Het 2 C 1-6 alkyl, optionally substituted amino-C 1-6 alkyl; R 6 is C 1-6 alkylO, Het 1 , Het 1 O, Het 2 , Het 2 O, aryl, arylO, C 1-6 alkyloxy-carbonylamino or amino; and in case -A- is other than C 1-6 alkanediyl then R 6 may also be C 1-6 alkyl, Het 1 C 1-4 alkyl, Het 1 OC 1-4 alkyl, Het 2 C 1-4 alkyl, Het 2 OC 1-4 alkyl, arylC 1-4 alkyl, arylOC 1-4 alkyl or aminoC 1-4 alkyl; whereby each of the amino groups in the definition of R 6 may optionally be substituted; R 5 and -A-R 6 taken together with the nitrogen atom to which they are attached may also form Het 1 or Het 2 ′ R 12 is H, —NH 2 , —NR 5 AR 6 , —C 1-6 alkyl or alkyl-W—R 14 , wherein said alkyl is optionally substituted with halogen, hydroxy, aryl, heteroaryl, Het 1 , Het 2 , or amino wherein said amino is optionally mono- or di-substituted with C 1-4 alkyl and R 13 is H, C 1-6 -alkyl, optionally substituted by aryl, Het 1 , Het 2 , hydroxy, halogen, amino whereby the amino group may be optionally be mono- or di-substituted with C 1-4 alkyl.